

Bibliografía

1. Ey H. *Traité des hallucinations*. Paris (France): Masson; 1973.
2. Yung AR, Yuen HP, McGorry PD, Phillips LJ, et al. Mapping the onset of Psychosis: The Comprehensive Assessment of At Risk Mental States. *Austr New Zealand J of Psychiat*. 2005;39(11-12):964-71.
3. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. *Schizophr Res*. 2003;61(1):7-18.
4. Yung AR, McGorry PD. The prodromal phase of first episode psychosis: Past and current conceptualisations. *Schizo Bulletin*. 1996;22: 353-70.
5. Yung AR, Phillips LJ, McGorry PD, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizo Research*. 2003;67:131-42.
6. Screening and treatment of adolescents with schizophrenia. The Hague (The Netherlands): Health Council of the Netherlands; 1999. Informe Núm. 1999/08E.
7. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry*. 1997;154 (4 Suppl):1-63.
8. Vázquez-Barquero JL, Cuesta Núñez MJ, de I, V, Herrera CS, Gaité L, Arenal A. The Cantabria first episode schizophrenia study: a summary of general findings. *Acta Psychiatr Scand*. 1995;91(3):156-62.
9. Murray RM. Epidemiological evidence concerning the diagnostic status of schizophrenia and bipolar disorder epidemiological [abstract of the XX International Congress on Schizophrenia Research]. *Schizophr Bull*. 2007;33(2):243.
10. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychol Med Monogr Suppl*. 1992;20:1-97.
11. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidente os schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. *Psychol Med*. 1986;16:909-28.

12. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. *Acta Psychiatr Scand.* 2005;111(1):4-11.
13. McGrath JJ. Variations. *Schizophr Bull.* 2006;32(1):195-7.
14. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med.* 2004;2:13.
15. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes - Findings from the 3 center AESOP study. *Arch Gen Psychiatry.* 2006;63(3):250-8.
16. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med.* 2005;2(5):413-33.
17. Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, et al. Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years. *Schizophr Bull.* 2005;31(3):624-38.
18. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. *Pharmacoepidemiol Drug Saf.* 2006;15(12):873-9.
19. McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. *J Clin Psychiatry.* 1999;60(Suppl 11):3-80.
20. Chinchilla Moreno A. Guía terapéutica de las esquizofrenias. Barcelona: Editorial Masson; 2000.
21. Practice guideline for the treatment of patients with schizophrenia [monografía en Internet]. American Psychiatric Association; 2004 [citado 2006]. Disponible en: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf
22. Consenso español sobre evaluación y tratamiento de la esquizofrenia. Madrid: Sociedad Española de Psiquiatría; 1998.
23. Falloon IR, Montero I, Sungur M, Mastroeni A, Malm U, Economou M, et al. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. *World Psychiatry.* 2004;3(2):104-9.
24. National Collaborating Centre for Mental Health. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London (United Kingdom): The Royal College of Psychiatrists & The British Psychological Society. National Institut for Clinical Excellence; 2003.

25. McGorry P, Parkville V, Killackey E, Elkins K, Lambert M. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). *Australas Psychiatry*. 2003;11(2):136-47.
26. Clinical practice guidelines. Treatment of schizophrenia. *Can J Psychiatry*. 2005;50(13 Suppl 1):7S-57S.
27. GPT 1. Guía de prescripción terapéutica. Información de medicamentos autorizados en España. Barcelona: Agencia española de medicamentos y productos sanitarios. Pharma Editores SL; 2006.
28. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry*. 1988;45(1):79-91.
29. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Møller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry*. 2006;7(1):5-40.
30. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Møller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. *World J Biol Psychiatry*. 2005;6(3):132-91.
31. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. *Schizophr Bull*. 2004;30(2):193-217.
32. Soler P, Gascón J. RTM III. Recomendaciones terapéuticas en los trastornos mentales. Comité de consenso de Catalunya en terapéutica de los trastornos mentales. 3a ed. Barcelona: Ars Medica; 2005.
33. Chinchilla Moreno A. Las esquizofrenias. Barcelona: Elsevier Masson; 2007.
34. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. *Schizophr Res*. 1991;4(2):109-20.
35. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. *JAMA*. 1961;175:1054-60.
36. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. *Psychopharmacol Bull*. 1992;28(1):81-6.
37. Villegas I, López Román F, Martínez González A, Villegas J. Obesidad y síndrome metabólico en pacientes con esquizofrenia. *Psiquiatr Biol*. 2005;12(2):39-45.
38. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National

- Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol.* 2004;24(8):e149-e161.
39. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. *J Clin Psychiatry.* 2005;66(4):504-14.
 40. Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. *Med J Aust.* 2004;181(10):544-8.
 41. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry.* 2006;18(3):183-94.
 42. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. *Schizophr Res.* 2004;71(2-3):195-212.
 43. Bellantuono C, Tentoni L, Donda P. Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach. *Hum Psychopharmacol.* 2004;19(8):549-58.
 44. Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. *Eur Psychiatry.* 2005;20 Suppl 4:S340-S344.
 45. Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, Buse J. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. *Br J Psychiatry Suppl.* 2004;47:S94-101.
 46. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. *Br J Psychiatry Suppl.* 2004;47:S87-S93.
 47. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry.* 2004;161(8):1334-49.
 48. Perfil de toxicidad de los antipsicóticos atípicos. *Butlletí Groc (Fundació Institut Català de Farmacologia de la Universitat Autònoma de Barcelona).* 2002;15(1). Disponible en: <http://www.icf.uab.es/informacion/boletines/bg/bg151.02e.pdf>.
 49. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med.* 2009;360(3):225-35.
 50. Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. *Ann Clin Psychiatry.* 1995;7(3):139-41.
 51. Hatta K, Takahashi T, Nakamura H, Fujii S, Yamashiro H, Asukai N, et al. Prolonged upper airway instability in the parenteral use of benzodia-

- zepine with levomepromazine. *J Clin Psychopharmacol*. 2000;20(1):99-101.
52. APA Practice Guideline Development Process [monografía en Internet]. Arlington, VA (US): The American Psychiatric Association (APA). Disponible en: <http://www.psych.org>
 53. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *Aust N Z J Psychiatry*. 2005;39(1-2):1-30.
 54. Rojo Rodés JE, Vallejo Ruiloba J. *Terapia electroconvulsiva*. Barcelona: Masson-Salvat; 1994.
 55. *La psicoterapia a la xarxa pública de Salut Mental y Adiccions* [documento de uso interno]. Barcelona; 2007.
 56. Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. *J Am Acad Psychoanal Dyn Psychiatry*. 2003;31(1):141-54.
 57. Gisbert C, coordinación. *Rehabilitación psicosocial del trastorno mental severo. Situación actual y recomendaciones*. Madrid: Asociación Española de Neuropsiquiatría (AEN); 2002. Cuaderno Técnicos núm. 6.
 58. *Consenso español de expertos para recomendaciones de actuación en el tratamiento de la esquizofrenia*. Madrid: Sociedad Española de Psiquiatría; 2000.
 59. *Strategies therapeutiques a long term dans les psychoses schizophréniques*. Paris (France): Fédération Française de Psychiatrie; 1994.
 60. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD000524. DOI: 10.1002/14651858.CD000524.pub2.
 61. Gaudio BA. Is symptomatic improvement in clinical trials of cognitive-behavioral therapy for psychosis clinically significant? *J Psychiatr Pract*. 2006;12(1):11-23.
 62. Tarrrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? *Behav Res Ther*. 2004;42(12):1377-401.
 63. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia. *J Nerv Ment Dis*. 2006;194(1):3-9.
 64. Penn DL, Mueser KT, Tarrrier N, Gloege A, Cather C, Serrano D, et al. Supportive therapy for schizophrenia: possible mechanisms and

- implications for adjunctive psychosocial treatments. *Schizophr Bull.* 2004;30(1):101-12.
65. Ávila Espada A, Poch Bullich J. Manual de técnicas de psicoterapia. Un enfoque psicoanalítico. Madrid: Siglo Veintiuno de España Editores, SA; 1994.
 66. Malmberg L, Fenton M. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. *Cochrane Database of Systematic Reviews* 2001, Issue 3. Art. No.: CD001360. DOI: 10.1002/14651858.CD001360.
 67. Pekkala E, Merinder L. Psicoeducación para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
 68. Pharoah FM, Mari JJ, Streiner D. Family intervention for schizophrenia. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD000088. DOI: 10.1002/14651858.CD000088.pub2.
 69. Barbato A, D'Avanzo B. Family interventions in schizophrenia and related disorders: a critical review of clinical trials. *Acta Psychiatr Scand.* 2000;102(2):81-97.
 70. Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia-a meta-analysis. *Schizophr Bull.* 2001;27(1):73-92.
 71. Huxley NA, Rendall M, Sederer L. Psychosocial treatments in schizophrenia: a review of the past 20 years. *J Nerv Ment Dis.* 2000;188(4):187-201.
 72. Pharoah F, Mari J, Rathbone J, Wong W. Intervención familiar para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
 73. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. *Schizophr Bull.* 2006;32 Suppl 1:S64-S80.
 74. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry.* 1998;55(6):547-52.
 75. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. *J Marital Fam Ther.* 2003;29(2):223-45.

76. Bustillo JR, Lauriello J, Horan WP, Keith SJ. Actualización del tratamiento psicosocial de la esquizofrenia. *Am J Psychiatr (Ed Esp)*. 2001;4(2):104-16.
77. Sellwood W, Barrowclough C, TARRIER N, Quinn J, Mainwaring J, Lewis S. Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. *Acta Psychiatr Scand*. 2001;104(5):346-55.
78. Barrowclough C, TARRIER N, Lewis S, Sellwood W, Mainwaring J, Quinn J, et al. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. *Br J Psychiatry*. 1999;174:505-11.
79. Panades R. La rehabilitación neuropsicológica del paciente esquizofrénico [tesis doctoral]. Barcelona: Universitat de Barcelona; 2002.
80. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? *J Psychiatry Neurosci*. 2004;29(2):102-13.
81. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Pritchard TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. *Am J Psychiatry*. 2000;157(8):1317-23.
82. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry*. 2007;164(12):1791-802.
83. Hayes RL, McGrath JJ. Cognitive rehabilitation for people with schizophrenia and related conditions. *Cochrane Database of Systematic Reviews* 2000, Issue 3. Art. No.: CD000968. DOI: 10.1002/14651858.CD000968.
84. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. *Am J Psychiatry*. 1996;153(12):1585-92.
85. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. *Am J Psychiatry*. 1998;155(8):1087-91.
86. National Collaborating Centre for Mental Health. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Draft for consultation [documento provisional]. London (United Kingdom): National Institute for Clinical Excellence; September 2008.
87. Modelo de Atención a personas con Enfermedad mental grave. Documento de consenso. Madrid: IMSERSO. Ministerio de Trabajo y Asuntos Sociales; 2006.

88. Drake RE, Mueser KT, Torrey WC, Miller AL, Lehman AF, Bond GR, et al. Evidence-based treatment of schizophrenia. *Curr Psychiatry Rep.* 2000;2(5):393-7.
89. Bond GR, Becker DR, Drake RE, Rapp CA, Meisler N, Lehman AF, et al. Implementing supported employment as an evidence-based practice. *Psychiatr Serv.* 2001;52(3):313-22.
90. Crowther R, Marshall M, Bond G, Huxley P. Rehabilitación vocacional para personas con enfermedades mentales graves (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 Número 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de *The Cochrane Library*, 2008 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).
91. Killackey EJ, Jackson HJ, Gleeson J, Hickie IB, McGorry PD. Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first-episode psychosis: employing cautious optimism. *Aust N Z J Psychiatry.* 2006;40(11-12):951-62.
92. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. *J Nerv Ment Dis.* 2003;191(8):515-23.
93. Lascorz D, Serrats E, Pérez V, Fábregas J, Vegué J. Estudio comparativo coste/eficacia de un dispositivo residencial para enfermos con trastorno mental severo. *Rev Asoc Esp Neuropsiquiatr.* 2009;103(1):191-201.
94. Burns T. *Community mental health teams. A guide to current practices.* New York, NY (US): Oxford University Press; 2005.
95. Malone D, Marriott S, Newton-Howes G, Simmonds S, Tyrer P. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD000270. DOI: 10.1002/14651858.CD000270.pub2.
96. Malm U, Ivarsson B, Allebeck P, Falloon IR. Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs. *Acta Psychiatr Scand.* 2003;107(6):415-23.
97. Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. Integrated treatment ameliorates negative symptoms in first episode psychosis--results from the Danish OPUS trial. *Schizophr Res.* 2005;79(1):95-105.
98. Killaspy H, Bebbington P, Blizard R, Johnson S, Nolan F, Pilling S, et al. The REACT study: randomised evaluation of assertive community treatment in north London. *BMJ.* 2006;332(7545):815-20.
99. Commander M, Sashidharan S, Rana T, Ratnayake T. North Birmingham assertive outreach evaluation. Patient characteristics and cli-

- nical outcomes. *Soc Psychiatry Psychiatr Epidemiol.* 2005;40(12):988-93.
100. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD001089. DOI: 10.1002/14651858.CD001089.
 101. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD000050. DOI: 10.1002/14651858.CD000050.
 102. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. *Schizophr Bull.* 1998;24(1):37-74.
 103. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. *BMJ.* 2007;335(7615):336.
 104. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry.* 2001;40(7 Suppl):4S-23S.
 105. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. *J Gen Intern Med.* 2006;21(11):1133-7.
 106. Kelly M, Lamah M. Evaluating the accuracy of data entry in a regional colorectal cancer database: implications for national audit. *Colorectal Dis.* 2007;9(4):337-9.
 107. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *J Clin Psychiatry.* 2004;65(2):267-72.
 108. Consenso sobre promoción de la salud mental, prevención del trastorno mental y disminución del estigma de la Asociación Española de Neuropsiquiatría. Madrid: Asociación Española de Neuropsiquiatría; 2007.
 109. Enfermedad mental: análisis de las actitudes de rechazo social y estigmatización que sufren las personas con enfermedad mental. Madrid: Consejería de Asuntos Sociales de la Comunidad de Madrid; 2006.
 110. McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical interven-

- tion in prepsychotic mental disorder. *Schizophr Bull.* 2003;29(4):771-90.
111. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry.* 2002;59(10):921-8.
 112. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. *Acta Psychiatr Scand.* 2006;113(4):247-72.
 113. Bechdolf A, Phillips LJ, Francey SM, Leicester S, Morrison AP, Veith V, et al. Recent approaches to psychological interventions for people at risk of psychosis. *Eur Arch Psychiatry Clin Neurosci.* 2006;256(3):159-73.
 114. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. *Eur Psychiatry.* 2005;20(5-6):372-8.
 115. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res.* 2004;67(2-3):131-42.
 116. Johannessen J, Martindale B, Culberg J. *Evolución de las psicosis.* Barcelona: Herder; 2008.
 117. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. *Schizophr Res.* 2006;83(1):29-40.
 118. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. *Am J Med Genet.* 2002;114(8):929-37.
 119. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. *Br J Psychiatry Suppl.* 2005;48:s116-s119.
 120. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. *Br J Psychiatry Suppl.* 2005;48(187):S120-S124.
 121. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? *Biol Psychiatry.* 1999;46(7):899-907.

122. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. *Am J Psychiatry*. 2005;162(12):2220-32.
123. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry*. 2003;160(8):1396-404.
124. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet*. 2008;371(9618):1085-97.
125. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry*. 2005;162(5):947-53.
126. Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Tor K, et al. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. *Early Interv Psychiatry*. 2009;3(1):58-65.
127. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry*. 2007;164(7):1050-60.
128. Jeppesen P, Petersen L, Thorup A, Abel M, Ehlerschlger J, Christensen T, et al. Integrated treatment of first-episode: effect of treatment on family burden. *Br J Psychiatry*. 2005;187:S85-S90.
129. Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. *Br J Psychiatry*. 2006;188:37-45.
130. Marshall M, Rathbone J. Early Intervention for psychosis. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD004718. DOI: 10.1002/14651858.CD004718.pub2.
131. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. *Br J Psychiatry Suppl*. 1998;172(33):53-9.
132. Edwards J, McGorry P. La intervención precoz en la psicosis: Guía para la creación de servicios de intervención precoz en la psicosis. Madrid: Editorial Fundación para el tratamiento de la esquizofrenia y otras psicosis; 2004.

133. Vishnu Gopal Y, Variend H. First-episode schizophrenia: review of cognitive deficits and cognitive remediation. *Adv Psychiatr Treat.* 2005;11:38-44.
134. Rinaldi M, McNeil K, Firm M, Koleti M, Perkins R. What are the benefits of evidence-based supported employment for patients with first-episode psychosis. *Psychiatr Bull.* 2004;28:281-4.
135. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. *Schizophr Bull.* 1996;22(2):201-22.
136. Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston-Cronk K, Zimmermann K, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. *Am J Psychiatry.* 1992;149(11):1549-55.
137. Wallace CJ, Liberman RP, MacKain SJ, Blackwell G, Eckman TA. Effectiveness and replicability of modules for teaching social and instrumental skills to the severely mentally ill. *Am J Psychiatry.* 1992;149(5):654-8.
138. Eckman TA, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. *J Clin Psychopharmacol.* 1990;10(1):33-8.
139. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. *J Nerv Ment Dis.* 2001;189(5):278-87.
140. Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: Effects on adjustment of patients. *Am J Psychiatry.* 1997;154(11):1514-24.
141. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: Description of study and effects on relapse rates. *Am J Psychiatry.* 1997;154(11):1504-13.
142. Psychosocial interventions in the management of schizophrenia. A national clinical guideline. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1998. SIGN publication núm. 30.
143. Crowther R, Marshall M, Bond G, Huxley P. Rehabilitaci3n vocacional para personas con enfermedades mentales graves (Revisi3n Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 N3mero 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2008 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).

144. Martens WH. A review of physical and mental health in homeless persons. *Public Health Rev.* 2001;29(1):13-33.
145. Acute Pain Management Guideline Panel. Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Rockville, MD (US): Public Health Service. Department of Health and Human Services; 1992.
146. Hospital inpatient management of acute asthma attacks source. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1996. Report Number 6.